Progesterone inhibits folic acid transport in human trophoblasts.
The aim of this work was to test the putative involvement of members of the ABC superfamily of transporters on folic acid (FA) cellular homeostasis in the human placenta. [(3)H]FA uptake and efflux in BeWo cells were unaffected or hardly affected by multidrug resistance 1 (MDR1) inhibition (with verapamil), multidrug resistance protein (MRP) inhibition (with probenecid) or breast cancer resistance protein (BCRP) inhibition (with fumitremorgin C). However, [(3)H]FA uptake and efflux were inhibited by progesterone (200 microM). An inhibitory effect of progesterone upon [(3)H]FA uptake and efflux was also observed in human cytotrophoblasts. Moreover, verapamil and ss-estradiol also reduced [(3)H]FA efflux in these cells. Inhibition of [(3)H]FA uptake in BeWo cells by progesterone seemed to be very specific since other tested steroids (beta-estradiol, corticosterone, testosterone, aldosterone, estrone and pregnanediol) were devoid of effect. However, efflux was also inhibited by beta-estradiol and corticosterone and stimulated by estrone. Moreover, the effect of progesterone upon the uptake of [(3)H]FA by BeWo cells was concentration-dependent (IC(50 )= 65 [range 9-448] microM) and seems to involve competitive inhibition. Also, progesterone (1-400 microM) did not affect either [(3)H]FA uptake or efflux at an external acidic pH. Finally, inhibition of [(3)H]FA uptake by progesterone was unaffected by either 4-acetamido-4'-isothiocyanato-2,2'-stilbenedisulfonic acid (SITS), a known inhibitor of the reduced folate carrier (RFC), or an anti-RFC antibody. These results suggest that progesterone inhibits RFC. In conclusion, our results show that progesterone, a sterol produced by the placenta, inhibits both FA uptake and efflux in BeWo cells and primary cultured human trophoblasts.
Department of Biochemistry (U38-FCT), Faculty of Medicine of Porto, University of Porto, Porto 4200-319, Portugal.
Elisa
E
Keating
Pedro
P
Gonçalves
Clara
C
Lemos
Fernanda
F
Costa
Isabel
I
Campos
Sylvia B
SB
Smith
Christy C
CC
Bridges
Fátima
F
Martel
D012856:4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid / Q000494:pharmacology; D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors / Q000187:drug effects* / Q000502:physiology; D004958:Estradiol / Q000494:pharmacology; D005492:Folic Acid / Q000378:metabolism*; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007700:Kinetics; D011339:Probenecid / Q000494:pharmacology; D011374:Progesterone / Q000494:pharmacology*; D014327:Trophoblasts / Q000187:drug effects* / Q000378:metabolism*; D014700:Verapamil / Q000494:pharmacology; D010130:p-Aminohippuric Acid / Q000494:pharmacology
D018528:ATP-Binding Cassette Transporters; D007211:Indoles; D012856:4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; D011374:Progesterone; D004958:Estradiol; D005492:Folic Acid; D014700:Verapamil; C010522:tryptoquivaline; D011339:Probenecid; D007213:Indomethacin; D010130:p-Aminohippuric Acid